Subscribe RSS
 
  • China BioIPR
  • 医药生物技术知识产权
  • 农业生物技术知识产权
  • 欧盟/德国知识产权法
  • 中国企业欧洲维权
  • About

Monthly Archives: August 2008

Neues Chinesische Patentgesetz in 2009: Patentanmeldung und Rechtsdurchsetzung

August 30, 2008 Posted by Zhuomin Wu under China BioIPR Watch
1 Comment

Chinesisches PatentgesetzesChina wird das neue Patentgesetz in 2009 erlassen. Die wichtigen Änderungen rechtzeitig zu kennen und dann IP Strategie anzupassen, ist für ausländische Unternehmen in China sehr wichtig. Änderungen im letzten offiziellen Entwurf, die den ausländischen Firmen von Bedeutung sind, werden hier kurz dargestellt.

(more…)

Fusion Protein | 融合蛋白质

August 27, 2008 Posted by 武卓敏 under 术语百汇-生物科技
No Comments

 

↓↓↓↓↓↓↓↓↓↓中文解释↓↓↓↓↓↓↓↓↓↓

融合蛋白

融合蛋白有两种不同的含义, 一种是通过DNA重组技术得到的两个基因重组后的表达产物。另一种含义就是介导两个细胞质膜融合的一组蛋白。(中文解释尚需完善,请参照下面的英文解释)

 

↓↓↓↓↓↓↓↓↓↓英文解释↓↓↓↓↓↓↓↓↓↓

Fusion proteins, also known as chimeric proteins, are proteins created through the joining of two or more genes which originally coded for separate proteins. Translation of this fusion gene results in a single polypeptide with function properties derived from each of the original proteins.

The functionality of fusion proteins is made possible by the fact that many protein functional domains are modular. In other words, the linear portion of a polypeptide which corresponds to a given domain, such as a tyrosine kinase domain, may be removed from the rest of the protein without destroying its intrinsic enzymatic capability.

Naturally occurring fusion genes are most commonly created when a chromosomal translocation replaces the terminal exons of one gene with intact exons from a second gene. This creates a single gene which can be transcribed, spliced, and translated to produce a functional fusion protein. Many important cancer-promoting oncogenes are fusion genes produced in this way.

Several drugs made from chimeric proteins are currently available for medical use. Several chimeric protein drugs are TNFα blockers, such as Etanercept, Infliximab, and Adalimumab.

_______________________________________


·

From Wikipedia, the free encyclopedia

· Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 or any later version published by the Free Software Foundation;with no Invariant Sections, no Front-Cover Texts, and no Back-Cover Texts.A copy of the license is included in the section entitled “GNU Free Documentation License”.

 

↓↓↓↓↓↓↓↓↓↓中文解释↓↓↓↓↓↓↓↓↓↓

融合蛋白

融合蛋白有两种不同的含义, 一种是通过DNA重组技术得到的两个基因重组后的表达产物。另一种含义就是介导两个细胞质膜融合的一组蛋白。(中文解释尚需完善,请参照下面的英文解释)

 

↓↓↓↓↓↓↓↓↓↓英文解释↓↓↓↓↓↓↓↓↓↓

Fusion proteins, also known as chimeric proteins, are proteins created through the joining of two or more genes which originally coded for separate proteins. Translation of this fusion gene results in a single polypeptide with function properties derived from each of the original proteins.

The functionality of fusion proteins is made possible by the fact that many protein functional domains are modular. In other words, the linear portion of a polypeptide which corresponds to a given domain, such as a tyrosine kinase domain, may be removed from the rest of the protein without destroying its intrinsic enzymatic capability.

Naturally occurring fusion genes are most commonly created when a chromosomal translocation replaces the terminal exons of one gene with intact exons from a second gene. This creates a single gene which can be transcribed, spliced, and translated to produce a functional fusion protein. Many important cancer-promoting oncogenes are fusion genes produced in this way.

Several drugs made from chimeric proteins are currently available for medical use. Several chimeric protein drugs are TNFα blockers, such as Etanercept, Infliximab, and Adalimumab.

_______________________________________


·

From Wikipedia, the free encyclopedia

· Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 or any later version published by the Free Software Foundation;with no Invariant Sections, no Front-Cover Texts, and no Back-Cover Texts.A copy of the license is included in the section entitled “GNU Free Documentation License”.

-->
Recent Posts
  • 中企欧洲维权:德国已成为欧洲知识产权诉讼的主要阵地
  • 中企欧洲维权(瑞士):天津海鸥手表在欧洲展会上成功对抗瑞士公司的侵权投诉
  • 中企欧洲维权启示:西班牙小公司成功撤销苹果公司iPad禁令
  • 德国展会知识产权纠纷系列: 一、中国企业遭围剿
  • 苹果vs三星德国临时禁令案:8月25日听证(附法院文件)
  • 中国赴德企业应警惕:苹果利用德国法院临时禁令让三星输市场大过输官司
  • 中国生物技术富人榜里难觅核心药品专利的影子
  • 2011年7月到期的美国药品专利
随机阅读
  • WIPO:2007年国际专利申请量前所未有
  • Dendritic cells | Dendritische Zellen | 树突细胞
  • 《IPLawg Review:知识产权网络评论》试刊第1卷第1期
  • 德国著作权集体管理组织有哪些?
  • 专利化进程与抑制高昂的药品价格
关键词阅读
生物制药 Geschmacksmuster 遗传资源 诉前临时措施 德国临时禁令 展会知识产权 Chinesisches Patentgesetz 强制许可 德国专利诉讼 专利药品 欧共体外观设计 欧洲专利 药品专利 海外维权 欧盟知识产权法
无标题文档

除特别说明,本站遵循“创作共用 CC BY-NC-ND 2.5 协议”(署名-非商业性使用-禁止演绎)保护著作权。详情参见About.

本站所有内容仅用于信息交流,不作为任何法律建议。

Except where otherwise noted, content on this site is licensed under Creative Commons Attribution-NonCommercial-NoDerivs 2.5 License. Details please see About.

This website DOES NOT provide any legal advice.

在线用户
Users: %GUESTS_SEPERATOR%5 Guests%BOTS_SEPERATOR%
最新评论
  • 中企欧洲维权(瑞士):天津海鸥手表在欧洲展会上成功对抗瑞士公司的侵权投诉 |BIOIPR on About
  • Zhuomin on 中国赴德企业应警惕:苹果利用德国法院临时禁令让三星输市场大过输官司
  • curcychen on 中国赴德企业应警惕:苹果利用德国法院临时禁令让三星输市场大过输官司
友情链接
  • 中国政法大学知识产权研究中心
  • 中国生物技术产业网
  • 中国知识产权司法保护网
  • 灵盾网
推荐关注
  • Welthungerhilfe
  • 壹基金
BIOIPR powered by WordPress and The Clear Line Theme